Overview of Efficacy and Limitation of Standard and Targeted Therapy for Malignant Disease Using Lung Cancer as a Case Study

  • Dao M. Nguyen


Recent advances in the understanding of the molecular basis of cancer have translated to the development of effective therapeutic modalities for certain types of malignant tumors. Significant percentages of solid tumors present with locally advanced or metastastic disease for which systemic chemotherapy, with or without radiotherapy, is the only treatment option. Cytotoxic drugs discovered by the screening of natural compounds or by medicinal chemistry are the mainstay of our current chemotherapy armamentarium for cancers. Only incremental improvements of therapeutic benefits have been achieved with the testing of different combinations and permutations of standard cytotoxic drugs given at maximal tolerable doses, leading to the notion that a therapeutic plateau has been reached for cancer chemotherapy. This provides impetus for the development of more innovative therapeutic strategies using newer drug schedules and novel agents targeting signal transduction pathways or cellular processes essential for cancer growth and metastasis. An overview of lung cancer therapy is used in this paper to illustrate the evolving paradigm of modern oncology. The future of cancer chemotherapy will most likely be a hybrid of cytotoxic drugs combined with molecularly targeted agents that are individually tailored to the patient’s specific genotype and phenotype. In this context, chemical libraries derived from natural products have the potential to identify novel agents with complex structure, chirality, and multiple pharmacophores suitable to interfere with single or multiple cancer targets.


Advanced NSCLC Malignant Pleural Effusion EGFR Mutation Mediastinal Lymph Node Metastasis Sublobar Resection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Adjuvant Navelbine International Trialist Association


Computed axial tomography


Epidermal growth factor receptor


European Organization for Research and Treatment of Cancer


Estrogen receptor


International Adjuvant Lung Cancer Trial Collaboratory Group


Magnetic resonance imaging


Non-small cell lung cancer


Positron emission tomography


Progesterone receptor


  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefGoogle Scholar
  2. 2.
    Jemal A, Seigel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.Google Scholar
  4. 4.
    Food and Drug Admionistration. (2008). Accessed 27 Oct 2008.
  5. 5.
    Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13 Suppl 1:5–13.PubMedCrossRefGoogle Scholar
  6. 6.
    Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist. 2007;12:1096–1104.PubMedCrossRefGoogle Scholar
  7. 7.
    Slotman B, Favire-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.CrossRefGoogle Scholar
  8. 8.
    Sobin L, Wittekind CH, editors. TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002. pp. 99–103.Google Scholar
  9. 9.
    Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (7th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2007;2:706–14.CrossRefGoogle Scholar
  10. 10.
    Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615–22.CrossRefGoogle Scholar
  11. 11.
    Okada M, Koike T, Higashiyama M, et al. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132:769–75.CrossRefGoogle Scholar
  12. 12.
    Koike T, Yamato Y, Yoshiya K, et al. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg. 2003;125:924–8.CrossRefGoogle Scholar
  13. 13.
    Phase III Randomized Study of Lobectomy Versus Sublobar Resection in Patients with Small Peripheral Stage IA Non-Small Cell Lung Cancer. (2008). Last accessed 26 Oct 2008.
  14. 14.
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995;311:899–909.Google Scholar
  15. 15.
    Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.CrossRefGoogle Scholar
  16. 16.
    Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–97.CrossRefGoogle Scholar
  17. 17.
    Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–60.CrossRefGoogle Scholar
  18. 18.
    Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.CrossRefGoogle Scholar
  19. 19.
    Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 2007;25:5506–18.Google Scholar
  20. 20.
    Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys. 2008;72:695–701.Google Scholar
  21. 21.
    Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–21.CrossRefGoogle Scholar
  22. 22.
    Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.CrossRefGoogle Scholar
  23. 23.
    Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25:5240–7.CrossRefGoogle Scholar
  24. 24.
    PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998;352:257–63.Google Scholar
  25. 25.
    Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006;24:2998–3006.PubMedCrossRefGoogle Scholar
  26. 27.
    Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998;21:1–6.PubMedCrossRefGoogle Scholar
  27. 28.
    Rosell R, Gómez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer. 1999;26:7–14.PubMedCrossRefGoogle Scholar
  28. 29.
    Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol. 2005;23:3257–69.CrossRefGoogle Scholar
  29. 30.
    Van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442–50.Google Scholar
  30. 31.
    Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) versus CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG9309). Proc Am Soc Clin Onc. 2005;23:624S.Google Scholar
  31. 32.
    Belvedere O, Grossi F. Lung cancer highlights from ASCO 2005. Oncologist 2006;11:39–50.PubMedCrossRefGoogle Scholar
  32. 33.
    Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg. 2008;86:912–20.CrossRefGoogle Scholar
  33. 34.
    Detterbeck FC, Jones DR, Kerstine KH, Naunheim KS. Lung cancer: special treatment issues. Chest. 2003;123:244S–58S.Google Scholar
  34. 35.
    Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with Locally-Advanced Non-Small-Cell Lung Cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000;48:1475–82.Google Scholar
  35. 36.
    Kelly K, Huang C. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol. 2008;3:664–73.CrossRefGoogle Scholar
  36. 37.
    Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26:2450–6.CrossRefGoogle Scholar
  37. 38.
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.CrossRefGoogle Scholar
  38. 39.
    Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol. 2004;22:785–94.CrossRefGoogle Scholar
  39. 40.
    Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol. 2004;22:777–84.CrossRefGoogle Scholar
  40. 41.
    Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892–9.Google Scholar
  41. 42.
    Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545–52.CrossRefGoogle Scholar
  42. 43.
    Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.CrossRefGoogle Scholar
  43. 44.
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.CrossRefGoogle Scholar
  44. 45.
    Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500.PubMedCrossRefGoogle Scholar
  45. 46.
    Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–11.CrossRefGoogle Scholar
  46. 47.
    Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26:2442–9.CrossRefGoogle Scholar
  47. 48.
    Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol. 2008;26:2745–53.Google Scholar
  48. 49.
    Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900–9.CrossRefGoogle Scholar
  49. 50.
    Shepherd FA, Tsao MS. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol. 2006;24:1219–20.CrossRefGoogle Scholar
  50. 51.
    Hotta K, Kiura K, Toyooka S, et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:632–7.CrossRefGoogle Scholar
  51. 52.
    Blumenschein G, Jr. Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol. 2008;3:S124–7.CrossRefGoogle Scholar
  52. 53.
    Giaccone G. The potential of antiangiogeneic therapy in non-small cell lung cancer. Clin Cancer Res. 2007;13:1961–70.CrossRefGoogle Scholar
  53. 54.
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Thoracic Surgery Section, Division of Cardiothoracic Surgery, The DeWitt Daughtry Family Department of Surgery Leonard M. Miller Faculty of MedicineUniversity of MiamiMiamiUSA

Personalised recommendations